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effects are highly context dependent with 
outcomes dependent on a host of factors 
such as the host species, cell type, lineage, 
and which Wnt member or receptor is 
initiating signaling.[1–7] During neuronal 
development, Wnt signaling is a critical 
pathway controlling and tightly regu-
lating development and patterning of the 
forebrain, midbrain, and hindbrain.[8–10] 
However, the nuances of regulated Wnt 
signaling during brain development are 
highlighted in other studies which have 
found varied effects of Wnt signaling 
during neurogenesis. For instance, Wnt 
stimulation has been shown to either defer 
neurogenesis or indeed promote it.[11] This 
is also evident by loss of Wnt pathway reg-
ulation via the Wnt messenger β-catenin 
through adenomatous polyposis coli 
(APC), which has been shown to decrease 
neuroblast and neural stem cell popula-
tions in the developing cortex.[12] Other 
studies have found that Wnt stimulation 
enhances neurogenesis. Hirabayashi et al. 
in 2006 reported that increased expression 
of Wnt7a induced neurogenesis of neural 
progenitor cells (NPCs) in vitro.[13]
The Wnt signaling cascade is of signifi-
cant interest to Parkinson’s disease, where there is a compelling 
clinical need for new cell or pharmacological therapies to restore 
or replace dopaminergic cell populations lost to the disease. Par-
kinson’s disease (PD) arises from the progressive degeneration 
of midbrain dopaminergic (mDA) neurons in the substantia 
nigra pars compacta (SNc). Wnt signaling is known to play a 
prominent role in dopaminergic neuron formation. Several 
studies suggest that mid brain dopaminergic (mDA) neurons 
require Wnt signaling for their generation.[14–17] In the midbrain, 
β-catenin signaling inhibits Sonic hedgehog (Shh) signaling and 
causes the induction of dopaminergic differentiation through 
the expression of DA markers.[16,17] Prakash et al. also showed 
that Wnt1 preserved Otx2 levels in the ventral midbrain, which 
is required to generate dopaminergic neurons.[18] Castelo-Branco 
et al. showed that Wnt-1 enhances the proliferation of Nuur1+ 
expressing precursors, while Wnt-5a enhanced the number of 
Nuur1+ precursors with a dopaminergic phenotype.[14]
SH-SY5Y is a well-established model cell line in Parkinson’s 
disease research. When cultured with neurotrophic factors, SH-
SY5Y may differentiate into neuron-like cells with neuronal 
Wnt signaling is a key developmental pathway that regulates dopaminergic 
progenitor cell proliferation and differentiation during neuronal development. 
This makes Wnt signaling an important therapeutic target for neurodegenera-
tive conditions such as Parkinson’s disease. Wnt signaling can be modulated 
using peptides such as UM206, which bind to the Wnt receptor Frizzled. 
Previous work has demonstrated remote activation of the Wnt pathway 
through Frizzled using peptide-functionalized magnetic nanoparticles (MNPs) 
with magnetic field stimulation. Using this technology, Wnt signaling is 
remotely activated in the neuronal cell line SH-SY5Y, and the phenotypic 
response to stimulation is assessed. Results indicate β-catenin translocaliza-
tion and activation of TCF/LEF responsive transcription in response to MNP 
and magnetic fields, which result in dopaminergic marker expression when 
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phorbol ester phorbol 12-myristate 13-acetate. This approach is translated 
into ex vivo postnatal rat brain slices modeling the developing nigrostriatal 
pathway. Dopaminergic marker expression is maintained in MNP-labeled 
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demonstrate the translational value of remote control of signal transduction 
for controlling neuronal precursor cell behavior and highlight the potential 
applications for controlled cell differentiation as part of cell therapies for 
neurodegenerative disease.
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Mechano-Activation
1. Introduction
Wnt signaling has many effects on cell behavior and controls 
fundamental cellular functions such as cell proliferation, migra-
tion, differentiation, and directs cell polarity. These pleiotropic 
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morphology while expressing typical neuronal markers such 
as betaIII-tubulin and MAP2.[19,20] Furthermore, SH-SY5Y 
may be specified toward dopaminergic-like neurons when cul-
tured with the phorbol ester phorbol 12-myristate 13-acetate 
(PMA).[21,22] SH-SY5Y have since become a popular cell line for 
in vitro modeling of neurodegenerative diseases such as Par-
kinson’s disease. Recent work has demonstrated a role for Wnt 
signaling during SH-SY5Y differentiation[23] and has shown 
that Wnt activation can protect SH-SY5Y from the toxic effects 
of 6-[OHDA].[24,25] In contrast, inhibition of Wnt signaling was 
shown to reduce differentiation and increase susceptibility to 
the cancer drug doxorubicin.[26]
Altogether this suggests that the Wnt pathway could be a key 
target for therapeutic intervention in Parkinson’s disease. How-
ever, the clinical application of Wnt proteins have been ham-
pered due to their complex biochemical nature and extensive 
post-translational modifications which confers hydrophobic 
properties and further complicates pharmaceutical produc-
tion.[27,28] Some of these issues may be circumvented by using 
MNP to target and activate Wnt receptors directly.
We have previously demonstrated the feasibility of remotely 
targeting and activating Wnt signaling in stem cells using pep-
tide-functionalized MNP targeted to Frizzled receptors, while 
using oscillating magnetic fields to control and amplify sign-
aling. We have also shown the potential applications of this 
approach in a tissue engineering context where Wnt-activating 
MNP was shown to initiate bone formation in an ex vivo 
chick femur model of bone development.[29,30] The efficacy 
of magnetic activation of receptors for tissue engineering is 
further demonstrated with other known and putative mecha-
nosensitive receptors such as the TREK1 ion channel,[31,32] 
PDGF receptor,[33] activin A type II receptor,[34] as well as inte-
grins.[35] In this study, we report on the feasibility of using 
peptide–MNP conjugates for remote mechanoactivation of 
Wnt signaling and augmentation of neuronal differentia-
tion and dopaminergic marker expression in SH-SY5Y cells. 
Expression of target Frizzled receptors was first confirmed in 
the SH-SY5Y cell line. Next, MNP were functionalized with a 
synthetic peptide known as UM206, the structure of which is 
based on a conserved fragment of Wnt3a and Wnt5a. UM206 
specifically binds to Frizzled 1 and 2 receptors and is able to 
trigger canonical Wnt signaling. UM206 exists in two confor-
mations, a linear and a cysteine bridged cyclic conformation, 
both of which can exhibit different effects on signaling activity 
in vitro.[36] Wnt pathway activation using either linear or cyclic 
UM206-conjugated MNP and oscillating magnetic fields was 
demonstrated in SH-SY5Y using Wnt reporter systems. The 
effect of remote Wnt pathway activation on SH-SY5Y dopa-
minergic differentiation was then explored in monolayer 
cultures in the presence of the dopaminergic differentiation 
factor PMA. Finally, the translation of this approach was dem-
onstrated in ex vivo postnatal rat brain slices, where MNP-
labeled cells were injected into the striatum and stimulated 
over 7 days. The overall aim of this research was to demon-
strate that remote MNP activation of Wnt signaling pathways 
in neuro-progenitor cells can regulate and fine tune neuronal 
marker expression. This technique has clear applications for 
in vitro developmental research and may be a useful signaling 
tool for future cell therapies.
2. Results
2.1. Frizzled Receptor Expression in SH-SY5Y Cells
Target receptor expression was first probed in SH-SY5Y cells 
cultured in basal using rt-PCR. A base level of expression for 
Frizzled 1 and 2 receptors was observed in SH-SY5Y cells 
(Figure 1A) with both receptors shown to be well expressed 
in comparison to the house-keeping gene GAPDH. SH-SY5Y 
was then subjected to RA and brain-derived neurotrophic 
factor (BDNF)-mediated neuronal differentiation, and q-rt-PCR 
was used to map changes in Frizzled gene expression during 
differentiation. Expression of both Frizzled 1 and Frizzled 2 
were found to increase after 4 days (trend only) and remained 
relatively constant up to day 12 where peak expression was 
observed with a significant increase in Frizzled 2 expression 
observed at this time point (Figure 1B). Immunocytochemistry 
was used to assess neuronal differentiation and Frizzled expres-
sion of differentiated SH-SY5Y cells. BetaIII-tubulin staining 
confirmed neuronal differentiation with most betaIII-tubulin 
positive cells also co-expressing Frizzled 1 and Frizzled 2 
receptors (Figure 1C).
2.2. Wnt Regulates Dopaminergic Gene Expression
The role of canonical Wnt signaling during RA- and BDNF-
induced neuronal differentiation was explored by assessment 
of dopaminergic gene markers after culture in different neu-
ronal induction media formulations containing RA, BDNF, and 
recombinant human Wnt3A. Addition of BDNF to RA media 
had minor stimulatory effects on dopamine receptor D2 (DRD2) 
and TH expression, respectively, and had no overall effect on 
dopamine receptor D3 (DRD3) and DAT expression. Incorpo-
ration of rhWnt into RA and BDNF media further increased 
DRD2, DRD3, and TH expression, respectively, with a significant 
increase for DRD2. However, no observable effect was observed 
on DAT expression. Replacement of BDNF with rhWnt reduced 
DRD2 expression to base levels, maintained TH expression, and 
caused a variable increase in DAT expression (Figure 2).
2.3. SH-SY5Y Labeling with MNP
Dextran-MNP with a diameter of 250 nm was functionalized 
with the Frizzled targeting peptide UM206 either in the linear 
conformation (Linear-UM206-MNP) or cyclic conformation 
(Cyclic-UM206-MNP). Dextran-coated particles were used in 
this study, as the dextran matrix protects the magnetite core, 
has low toxicity, confers bio-compatibility, and is amenable for 
clinical translation.[37–40] SH-SY5Y cells were then labeled with 
either UM206-MNP types or non-specific control (IgG)-MNP. 
Immunocytochemistry to stain the MNP-dextran matrix was 
then performed to qualitatively assess MNP association with 
the cells. Fluorescent microscopy confirmed Linear-UM206-
functionalized MNP (L-UM206-MNP), Cyclic-UM206-MNP 
(C-C-UM206-MNP), and Control (IgG)-MNP, all bound to cells 3 
h after labeling. Labeling efficiency was similar across all groups 
(Figure 3A). Confocal microscopy was then used to determine 
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the sub-cellular location of MNP. Post labeling, MNP remained 
predominantly bound to the cell membrane (Figure 3B(i–iv)).
2.4. UM206-MNP Initiate β-Catenin Activation
The effect of both Linear and Cyclic-UM206-MNPs on down-
stream Wnt pathway activity in SH-SY5Y cells was then 
assessed. The mobilization of the Wnt pathway messenger 
β-catenin in response to UM206-MNP was first assessed 
using immunocytochemistry. Cells were treated with UM206-
MNP (linear or cyclic) or Control (IgG)-MNP and stimulated 
with or without magnetic field stimulation for 3 h. β-catenin 
activation was found to be elevated after treatment with Cyclic 
UM206-MNP alone (C-C-UM206-MNP) to a similar level as 
Wnt-CM after 24 h, while Linear-UM206-MNP (L-UM206-MNP) 
appeared to have a negligible effect (non-significant). An added 
effect was observed when either Linear or Cyclic-UM206-MNPs 
were applied in conjunction with magnetic field stimulation. 
In contrast, control MNP conjugated with non-specific-IgG 
(Control (IgG)-MNP) had a negligible effect on β-catenin acti-
vation with or without magnetic field treatment (Figure 4A). 
The trend was confirmed after the percentage of activated cells 
(cells containing active β-catenin) was quantified. Significant 
increases in β-catenin-positive cells were observed after treat-
ment with L-UM206-MNP only when combined with magnetic 
field stimulation, C-C-UM206-MNP (with or without magnetic 
field), or Wnt-CM. In contrast control groups treated with mag-
netic field alone or Control (IgG)-MNP had no effect over the 
non-treated cells only control (Figure 4B).
2.5. UM206-MNP Induce TCF/LEF Signaling
SH-SY5Y was then transfected with a TCF/LEF-responsive lucif-
erase reporter and treated with UM206-MNP with or without 
magnetic field stimulation. Reporter activity was elevated after 
treatment with either Linear UM206-MNP (L-UM206-MNP) 
or Cyclic UM206-MNP (C-C-UM206-MNP) after 6 h with 
increased activity observed with C-C-UM206-MNP, thereby 
confirming UM206-MNP-mediated activation of Wnt signaling 
in the SH-SY5Y cell line (Figure 5A(i)). An added effect was 
then observed when either UM206-MNP types were applied in 
conjunction with magnetic field stimulation, suggesting a ben-
eficial effect of magnetic-mediated mechanoactivation on Wnt 
pathway activity. In contrast, treatment with Wnt-CM caused a 
mild (non-significant) activation at this time point. After 24 h, 
reporter activity remained elevated in response to UM206-MNP 
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Figure 1. Frizzled receptors are expressed by SH-SY5Y during neuronal differentiation. Reverse transcription-PCR confirmed Frizzled 1 and 2 expression 
in SH-SY5Y in basal conditions, n = 3 (S1–3 = sample 1–3, NTC = no template control) (A). Frizzled 1 and 2 were both up-regulated during SH-SY5Y neu-
ronal differentiation using RA and BDNF as shown by quantitative reverse transcription-PCR; n = 4; error bars represent SEM; * represents p < 0.05 (B). 
RA and BDNF differentiated cells expressing β3-tubulin also co-expressed Frizzled 1 and 2 (C); representative images of n = 3; bar represents 25 µm.
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with similar responses to both UM206-MNP types observed. 
The activation response by UM206-MNP was also found to 
be comparable to Wnt-CM (also significant) at this time point 
(Figure 5A(ii)). In contrast to the Frizzled targeted MNP, con-
trol-MNPs functionalized with RGD peptide (RGD-MNP) or 
non-specific IgG (Control (IgG)-MNP) were used to induce 
generic membrane stimulation. Both of these control MNPs 
caused non-significant fluctuations on reporter activity with no 
overall effect observed (Figure 5B(i–ii)).
2.6. UM206-MNP Enhance Dopaminergic Marker Expression in 
Dopaminergic Media
The effect of Wnt-targeted MNP on dopaminergic differentia-
tion was then evaluated using immunocytochemistry to assess 
expression of key dopaminergic markers DAT and TH. Cells 
were cultured in reduced serum neuronal induction media 
(RA media) for 3 days, then labeled with MNP. Media was then 
switched to dopaminergic induction media containing PMA for 
further 4 days with intermittent magnetic stimulation. Overall 
expression of dopaminergic markers DAT and TH was main-
tained by Wnt pathway activating MNP (UM206-MNP) with or 
without magnetic field stimulation, with localized increases in 
marker expression observed in some cell populations. In con-
trast, non-specific Control (IgG)-MNP (either with or without 
magnetic stimulation) and Wnt-CM had no discernible effect 
on dopaminergic marker expression, which remained compa-
rable to base levels observed in the control groups (Figure 6A). 
Quantification of the TH/DAT-positive cell numbers confirmed 
this trend. An overall marginal increase in TH/DAT-positive cell 
numbers was observed in response to either L-UM206-MNP 
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Figure 2. Wnt3a synergizes with RA or BDNF to regulate dopaminergic gene expression. Gene expression analysis of dopaminergic genes (DRD2, 
DRD3, TH, and DAT) in response to different serum-free media formulations incorporating RA, BDNF, and rhWnt3a. Addition of BDNF to RA media 
led to minor (trend only) increases in DRD2 and TH expression and had no overall effect on DRD3 and DAT expression. Incorporation of rhWnt into 
RA and BDNF media further increased DRD2, DRD3, and TH expression (significant increase in DRD2) but had no observable effect on DAT expres-
sion. Replacement of BDNF with rhWnt reduced DRD2 expression to base levels, maintained TH levels, and caused variable increases in DAT expres-
sion. Figures show mean fold change in gene expression compared to RA alone; expression was normalized to 18S; error bars represent SEM; n = 4; 
*denotes p < 0.05.
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Figure 3. Labeling of SH-SY5Y with functionalized MNP. A) Immunofluorescence images showing unlabeled cells (top row) and cells labeled with 
L-UM206-MNP (second row), C-C-UM206-MNP (third row), and Control (IgG)-MNP (bottom row). Nuclei are shown by DAPI staining (blue); MNP 
are shown by anti-dextran staining (green); and cell cytoskeleton by Actin staining (red). Representative images of n = 3; scale bar represents 25 µm. 
B) Confocal microscopy confirmed that most MNP are bound at the cell membrane 3 h post-labeling. Cells alone are shown in (i), L-UM206-MNP 
(ii), C-C-UM206-MNP (iii), and Control (IgG)-MNP (iv). Nuclei are shown by DAPI staining (blue), MNP by anti-dextran staining (green), and cell 
membrane by CM-Dil staining (red). Representative images of n = 3; scale bar represents 30 µm.
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Figure 4. UM206-MNP initiates β-catenin activation. Active β-catenin mobilization was visualized by immunofluorescence 24 h after 3 h (1 Hz) mag-
netic stimulation. Untreated cells and cells treated with L-UM206-MNP or Control (IgG)-MNP showed negligible levels of β-catenin activation (A(i)), 
while addition of Wnt3A-conditioned media (Wnt-CM) or C-C-UM206-MNP resulted in minor increases in nuclear translocation over baseline levels. 
Treatment with magnetic field stimulation alone or with Control (IgG)-MNP had no observable effect on β-catenin translocation over basal levels, while 
an increase over the magnetic field–only control was observed when cells were treated with L-UM206-MNP or C-C-UM206-MNP with magnetic field 
stimulation (A(ii)). Cell nuclei are shown by DAPI staining (middle row). Representative images of n = 3; scale bar represents 25 µm. Quantification of 
active β-catenin cell numbers confirmed this trend with significant increases in active β-catenin positive cells after treatment with L-UM206-MNP (with 
magnetic field only), C-C-UM206-MNP (with or without magnetic field), or Wnt-CM. In contrast, control groups treated with magnetic field alone or 
Control (IgG)-MNP had no overall effect on active β-catenin cell numbers (B). Error bars represent SEM; n = 3; * denotes p < 0.05.
www.adv-biosys.comwww.advancedsciencenews.com
1900091 (7 of 13) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
or C-C-UM206-MNP treatment alone (trend only). Addition of 
magnetic field stimulation augmented this effect with a signifi-
cant increase in TH/DAT-positive cells observed after treatment 
with C-C-UM206-MNP with magnetic field stimulation. In con-
trast, TH/DAT-positive cell numbers remained comparable to 
the non-treated control after treatment with either magnetic 
field alone, Wnt-CM, or Control (IgG)-MNP with or without 
magnetic stimulation (Figure 6B).
2.7. MNP Maintain TH Expression in Injected Cells Cultured in 
Rat Brain Slices
Due to the increased signaling response to C-C-UM206-MNP, 
these MNPs were then used in subsequent ex vivo experi-
ments. Both C-C-UM206 and Control (IgG)-MNP-labeled cells 
were delivered into the striatum of postnatal rat brain slices 
and intermittently treated with magnetic field stimulation over 
7 days. Slices were cultured in RA-supplemented media for 3 
days followed by PMA-supplemented media for further 4 days 
to support dopaminergic differentiation of injected cells. Fluo-
rescent microscopy confirmed that cells were still present at the 
striatum injection site after 7 days, as shown by Pkh26 staining 
(Figure 7A). Furthermore, some populations of injected cells 
were found to express TH at levels which were broadly con-
sistent across all groups (Figure 7B), indicating a dopamin-
ergic-like phenotype.
3. Discussion
In this study, we examined the role of Wnt signaling in neu-
ronal differentiation of SH-SY5Y cells and probed the neuro-
genic effects of remote mechanoactivation of Wnt signaling 
using magnetic nanoparticles and magnetic fields. We first 
examined basal Frizzled receptor expression levels in SH-SY5Y. 
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Figure 5. UM206-MNP induces TCF/LEF reporter activation. A TCF/LEF responsive luciferase reporter was used to assess end point Wnt signaling 
after 3 h (1 Hz) treatment with MNP and magnetic stimulation. After 6 h, treatment with L-UM206-MNP or Wnt-CM resulted in marginal increases in 
reporter activity, while treatment with C-C-UM206-MNP resulted in significant reporter activation. Treatment with magnetic field alone had no signifi-
cant effect on reporter activity. In contrast, treatment with either L-UM206-MNP or C-C-UM206-MNP with added magnetic field stimulation resulted 
in significant reporter activation (A(i)). The same trend continued up to 24 h with significant reporter activity observed in response to L-UM206-MNP 
(with magnetic field) and C-C-UM206-MNP (with or without magnetic field). Wnt-CM also significantly increased reporter activity at this time point 
(A(ii)). Control particles functionalized with either RGD peptide (RGD-MNP) or IgG (Control IgG-MNP) caused no significant increases in reporter 
activity after at 6 h (B(i)) or 24 h (B(ii)). Error bars represent SEM; n = 4. * denotes p < 0.05.
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Figure 6. UM206-MNP enhances dopaminergic marker expression in dopaminergic media in vitro. Fluorescent images showing DAT (green) and TH 
(red) after 7 days of intermittent magnetic stimulation (3 h, 1 Hz). DAPI was used to visualize cell nuclei (blue). Non-treated cells and Control-MNP 
treated cells both showed a base level of DAT and TH expression, while treatment with L-UM206-MNP or C-C-UM206-MNP (without magnetic field) or 
Wnt-CM over 7 days resulted in marginal changes in DAT and TH expression. Both markers were largely unaffected by magnetic field stimulation alone. 
In contrast, treatment with L-UM206-MNP or C-C-UM206-MNP with magnetic field resulted in increases in DAT and TH expression over magnetic 
field–only control. Control (IgG)-MNP with magnetic field treatment reduced marker expression to control levels (A). Representative images of n = 3; 
scale bar = 100 µm. Quantification of TH/DAT-positive cell numbers confirmed this trend with increases in overall TH/DAT-positive cell numbers in 
response to either L-UM206-MNP or C-C-UM206-MNP alone (trend only). Addition of magnetic field stimulation augmented this effect with significant 
increases in TH/DAT-positive cells observed after treatment with C-C-UM206-MNP with magnetic field stimulation (B). Error bars represent SEM; 
n = 3; * denotes p < 0.05.
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We confirmed that both Frizzled 1 and 2 are expressed in SH-
SY5Y, consistent with Wei et al.,[24] who also showed Frizzled 1 
is expressed in SH-SY5Y (Frizzled 2 was not studied). The 
increasing expression of Frizzled receptors during RA- and 
BDNF-induced neuronal differentiation also suggests a role 
for Wnt signaling, particularly during the early stages of neu-
ronal differentiation. Furthermore, our observation that dif-
ferentiated neuronal cells also co-expressed Frizzled receptors 
is further evidence that Wnt signaling is important in mature 
neuronal function. These results are to be expected given the 
well-established link between Wnt signaling and neuronal 
development. Other groups have also alluded to the role of Wnt 
signaling during neuronal stem and pre-cursor cell differen-
tiation.[14,16–18] Our results also suggest that cross-talk between 
the Wnt pathway and RA and BDNF signaling is important 
for regulation of neuronal differentiation. Previous work has 
demonstrated the link between RA, BNF, and Wnt signaling. 
For example, Yang et al. showed that BDNF overexpression 
promoted the growth of human embryonic spinal cord neu-
rons and upregulated Wnt, Frizzled, and Dsh expression.[41] 
Uemura et al. showed that retinoic acid (RA) causes increases 
in nuclear β-catenin levels with subsequent increases in cyclin 
D1 expression.[42] Furthermore, RA has also been shown to 
activate WNT1 signaling, while repressing expression of Wnt 
antagonists.[43]
We then confirmed that it was possible to remotely activate 
the Wnt pathway in SH-SY5Y using mechano-stimulation of 
Frizzled receptors mediated by magnetic fields and peptide-
functionalized MNP. In this study, dextran-coated particles were 
functionalized with UM206 peptides allowing specific binding 
to Frizzled receptors expressed at the cell membrane. This 
allowed remote stimulation and activation of the Wnt signaling 
cascade by applying an external oscillating magnetic field which 
generates a torque on the MNP–receptor complex with forces in 
the pN range, as described previously.[29,44] Mechanoactivation 
of Wnt signaling has been previously reported through mul-
tiple mechanisms. Subjecting human mesenchymal stem cells 
(hMSCs) or osteoblasts to oscillatory shear stress or dynamic 
mechanical strain has been shown to promote β-catenin mobili-
zation and TCF/LEF-responsive gene transcription.[45–47] While 
further work is required to ascertain the precise mechanism of 
MNP-mediated activation of Frizzled receptors, our previous 
work suggests that Frizzled clustering may be part of this initial 
activation mechanism, an effect which may be enhanced upon 
magnetic oscillation of the receptor-bound MNP.[30] However, 
endocytosis of the Wnt-receptor signalosome is also known 
to play a role in Wnt signal transduction.[48,49] Due to the fact 
that MNPs are also commonly endocytosed by target cells,[50] 
internalization of the receptor-bound MNPs may in fact also 
play a role in MNP-mediated signaling. The long-term uptake 
and ultimate fate of receptor-bound MNP was not investigated 
in the current study, and these remain intriguing questions for 
future studies to explore.
Downstream indicators of Wnt pathway activity in response 
to UM206-MNP were investigated by assessing the hallmarks 
of Wnt pathway activation: β-catenin localization and end-point 
activation of TCF/LEF-responsive signaling.[51] Our results 
demonstrate that both L-UM206-MNP and C-C-UM206-MNP 
were capable of initiating nuclear translocation of β-catenin and 
activating TCF/LEF reporter expression in SH-SY5Y cells, espe-
cially when combined with magnetic field stimulation. These 
results are in agreement with our previous study which showed 
remote UM206-MNP-mediated activation of Wnt signaling in 
Figure 7. MNP maintains TH expression in injected cells cultured in ex 
vivo rat brain slices. Fluorescent and light microscopy images showing 
location of Pkh26-labeled cells 7 days after injection into the striatum of 
rat brain slices of the nigrostriatal pathway (A). Cells are shown by Pkh26 
staining (red). Rat brain tissue is shown in the light channel. The approxi-
mate striatum boundary is denoted by the dotted line. Representative 
images of n = 3; scale bar = 200 µm. TH expression was detected in some 
populations of injected cells in the striatum (indicated by arrows) after 
7 days of intermittent magnetic stimulation (3 h, 1 Hz), with expression 
levels broadly consistent across all groups (B). Representative images of 
n = 3; scale bar = 100 µm.
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hMSCs.[30] Interestingly, in contrast to our previous work in 
hMSCs, in SH-SY5Y cells, we observed broadly comparable 
pathway activation between L-UM206 and C-C-UM206-MNP, 
with somewhat increased pathway activity observed after 
C-C-UM206-MNP treatment. The activity of C-C-UM206-MNP 
may be expected given that the cyclic peptide has previously 
been shown to induce TCF/LEF activity.[36] One explanation for 
the cell-type dependent effects of these peptides could be differ-
ences in receptor expression levels between the two cell types; 
this could conceivably alter the binding kinetics of the function-
alized MNP and therefore alter the degree of pathway activation 
between the two peptide conformations.
We then sought to elucidate the effects of MNP-mediated 
Wnt pathway activation on SH-SY5Y cell fate. Wnt activation 
using UM206-MNP was shown to augment dopaminergic dif-
ferentiation of SH-SY5Y in conjunction with the Phorbol ester 
PMA. This demonstrates that mechanoactivated Wnt signaling 
can be a beneficial and synergistic stimulus for regulating 
dopaminergic differentiation of neuronal precursor cells. In 
this study, mechanoactivation was combined with the phorbol 
ester PMA, which has been previously shown to induce neurite 
extension and up-regulate BDNF, NeuN, and neuron-specific 
enolase expression,[52–55] while promoting tyrosine hydroxylase 
expression possibly through protein kinase C activation.[56] In 
the context of this work, our results could be expected given the 
neurogenic and dopaminergic phenotype inducing role of both 
PMA and Wnt signaling.
As dopaminergic differentiation is tightly controlled in vivo 
and relies on a number of pathways, it is therefore important 
to acknowledge the reciprocal role of Wnt signaling as part of 
a network of signaling pathways, such as PMA-induced sign-
aling, which are required for properly controlled dopamin-
ergic neuron development and function. Future work should 
investigate MNP-mediated control over differentiation of neu-
ronal stem cells as well as tracking the long-term phenotype of 
MNP-differentiated cells. Our results clearly highlight the com-
plex and contrasting role of Wnt signaling in regulating dopa-
minergic differentiation. In our study, in contrast to transient 
MNP-mediated Wnt activation, combining PMA with a constant 
Wnt3A signal provided by Wnt-conditioned media led to negli-
gible changes on dopaminergic marker expression. This indi-
cates that a constant canonical Wnt signal may be restricting 
terminal differentiation of some cells. This effect has also been 
observed in ventral midbrain (VM) cells treated with Wnt3a, 
which expanded the cell population but restricted their dopa-
minergic differentiation.[14] Incidentally, this effect was also 
mirrored in our previous work which showed that hMSC dif-
ferentiation was reduced in Wnt-conditioned media cultured 
cells.[30] Given the complex role of Wnt signaling in regulating 
dopaminergic differentiation, this result may also be expected. 
In the context of dopaminergic differentiation, Castelo-Branco 
et al. elegantly demonstrated the opposing effects that Wnt 
signaling can have on dopaminergic differentiation of precursor 
cells. In their study, canonical Wnt3a was shown to enhance 
Nurr1+ dopaminergic precursor cells while restricting TH+ cell 
numbers; in contrast, non-canonical Wnt5a led to enhancement 
of TH+ cells from Nurr1+ populations.[14] This suggests that 
canonical Wnt signaling may be beneficial in progenitor popu-
lations while withdrawal of Wnt or a switch to non-canonical 
signaling may be required for terminal dopaminergic differenti-
ation. In summary, our results highlight the beneficial role that 
transient and controlled activation of Wnt signaling with MNP 
can have on neuronal differentiation as opposed to a constant 
Wnt stimulus provided by exogenous Wnt protein.
We then sought to translate our approach into an ex vivo 
model of the nigrostriatal pathway. We demonstrated delivery 
of MNP-labeled cells into postnatal rat brain slices and showed 
that ex vivo stimulation of MNP-labeled cells had a similar, if 
somewhat restricted, effect on dopaminergic marker expression 
in this model. This suggests that paracrine factors in the host 
tissue may also be regulating implanted cell behavior. Indeed, 
other groups have shown that fibroblast growth factors, Shh, as 
well as both canonical and non-canonical Wnts are expressed 
in the ventral midbrain during development.[10,14,15,17,57] It is 
therefore feasible that the complex spatial and signaling cues 
that are replicated in ex vivo slice models may directly influ-
ence the fate of delivered cells by regulating multiple pathways, 
including Wnt Signaling. This serves to show the importance 
of controlling external spatial and biochemical cues for optimal 
differentiation of implanted cells and highlights one of the 
major challenges that must be overcome for successful adop-
tion of cell therapies in neurodegenerative disease.
4. Conclusion
In conclusion, there is considerable interest in developing Wnt 
modulators to therapeutically regulate Wnt signaling. Easily 
synthesized ligands conjugated to magnetic nanoparticles there-
fore present an attractive route for targeting cell signaling path-
ways. The use of conjugated MNP to activate Wnt signaling may 
have useful applications as a research tool or in drug discovery 
in an approach that is amenable to translation to the clinic. 
Furthermore, the ability to tune signaling activity by inducing 
MNP torque using external magnetic fields affords flexible and 
temporal control over the translational forces applied to target 
receptors and subsequent activation of differentiation pathways. 
Our results demonstrate that remote activation of cell signaling 
pathways using targeted magnetic particles and alternating 
magnetic fields can be used to influence neuronal cell signaling 
and precursor cell differentiation toward a dopaminergic pheno-
type. This unique approach opens a potential avenue for novel 
therapeutic treatments, in the form of injectable cell therapies, 
with potential applications for treating neurodegenerative dis-
eases such as Parkinson’s disease.
5. Experimental Section
Cell Culture: SH-SY5Y cells (PHE, UK) were grown to confluency in 
basal media consisting of DMEM:F12 (Corning) supplemented with 1% 
antibiotics and 10% fetal bovine serum (FBS) (Gibco) and incubated at 
37 °C and 5% CO2. Culture medium was replaced twice per week, and 
cells were passaged once they reached approximately 80% confluency. 
Cells of passage 18–28 were used in all experiments. For neuronal 
differentiation, after seeding on pre-coated laminin (Sigma) plates, cells 
were cultured in basal media for 24 h to allow cell attachment. Cells 
were differentiated in neuronal induction media as described in Figure 
S1, Supporting Information. Briefly, media was changed to neuronal 
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differentiation media consisting of basal media with the addition 
of 10 mm RA (Sigma) for 4 days after which media was switched to 
serum-free media with RA and 25 ng mL−1 BDNF (R&D systems) 
for a minimum of 8 days. Neuronal differentiation was confirmed 
microscopically by observing morphology changes and by staining for 
betaIII-tubulin (Figure S2, Supporting Information). Alternatively, cells 
were differentiated in modified neuronal media to support dopaminergic 
differentiation according to Knaryan et al.[21] Cells were cultured in 
reduced serum (3% FBS) media containing 10 mm RA for 3 days followed 
by 80 nm PMA (Sigma) for further 4 days. For Wnt media experiments, 
differentiation media was supplemented with 100 ng mL−1 recombinant 
human WNT3a (R&D systems), or diluted (1:5) Wnt-conditioned media 
(collected from Wnt3a overexpressing L-M (TK-) cells (ATCC).
MNP Functionalization: 250 nm of SPIO carboxyl–functionalized 
magnetic nanoparticles (Micromod, Germany) were covalently coated 
with UM206 peptide/RGD or rabbit-IgG (Abcam) by carbodiimide 
activation method, as described previously.[30] Briefly, 2 mg of particle 
suspension (for each ligand) was activated with EDAC/NHS in 0.5 m 
MES buffer (Sigma) for 1 h at room temperature. After washing, particles 
were coated overnight at 4 °C with 20 µg of either Linear-UM206 peptide, 
Cyclic-UM206 peptide (Pepceuticals, UK), RGD (Sigma), or 40 µg of anti-
rabbit-IgG (Abcam) in 0.1 m MES buffer (Sigma). For Control (IgG)-MNP, 
the suspension was washed in 0.1 m MES buffer, then re-suspended in 
0.1 m MES containing 20 µg of rabbit-IgG (Abcam) and mixed at room 
temperature for 3 h. All particle suspensions were blocked with 25 mm 
glycine (Sigma), washed in PBS (Lonza), and re-suspended in 1 mL 
PBS (Fisher). MNP functionalization was confirmed using dynamic 
light scattering and zeta potential (see Supporting Information). The 
peptide/protein coating on the MNP surface was quantified and number 
of ligands per MNP estimated using a total protein assay as described 
in Supporting Information. MNP morphology was also characterized by 
transmission electron microscopy (Figure S3, Supporting Information).
Cell MNP Labeling: Cells were cultured in reduced serum basal 
media for 3 h prior to addition of 25 µg MNP/2 × 105 cells. Cells were 
incubated with MNP for 1.5 h and then washed with PBS to remove 
unbound particles before addition of fresh media.
Magnetic Stimulation: Magnetically stimulated groups were treated 
with ≥25 mT magnetic fields provided by arrays of NdFeB magnets 
in 1–3 h sessions at 1 Hz using a vertically oscillating magnetic force 
bioreactor (MICA Biosystems, UK). The bioreactor was housed in a cell 
culture incubator maintained at 37 °C, 5% CO2.[29,30] Non-stimulated 
control groups were kept in identical external conditions (without 
magnetic field).
Transient Transfections: Cells were transiently transfected with a 
Gaussia luciferase reporter under control of an 8× TCF/LEF promoter, 
as described previously.[29,30] Briefly, cells were grown to approximately 
70% confluency in antibiotic-free media in 24-well plates. Cells were 
then transfected with 0.5 µg of TCF/LEF reporter in reduced serum 
Opti-MEM using Lipofectamine LTX reagent (Invitrogen) according to 
the manufacturer’s instructions. Transfection media was aspirated after 
4 h and replaced with fresh basal media. Luciferase activity was assessed 
48–72 h after transfection using Biotek Synergy 2 plate reader.
Luciferase Reporter Assays: Experiments were performed in reduced 
serum basal media in 24-well plates. At each time point, media samples 
were taken and analyzed for secreted Gaussia luciferase activity using 
a luciferase flash assay kit (Thermo Pierce) on a Biotek Synergy 2 plate 
reader operating Gen5 software. Luciferase activity was normalized to 
the total protein content of the respective cell lysates obtained at the 
experimental end-point and quantified using a BCA assay kit (Fisher).
Polymerase Chain Reaction: Total RNA was extracted using an 
RNAeasy extraction kit (Qiagen) according to the manufacturer’s 
instructions. Reverse transcription was performed on 1 µg RNA using a 
high-capacity reverse transcription kit (Applied Biosystems). Polymerase 
chain reaction (PCR) mixes were prepared using diluted cDNA mixed 
with PCR master mix (Applied Biosystems) and commercially available 
primers for Frizzled 1, Frizzled 2, DRD2, DRD3, TH, DAT, 18S, and 
GAPDH (Qiagen). Thermocycling was performed on a Stratagene 
MX3000P system. Gene expression was normalized to GAPDH or 18S as 
stated. Fold change in gene of interest expression was calculated using 
the delta-delta CT method. PCR products were resolved on a 2% agarose 
gel and imaged using a GelDoc-It2 imager system (UvP).
Immunocytochemistry: For establishment of neuronal differentiation and 
receptor expression targets, cells were stained with β3-tubulin (Abcam) 
diluted 1:1000 and either anti-Frizzled 1 (Santa Cruz) diluted 1:200 or anti-
Frizzled 2 (Santa Cruz) diluted 1:200. All primary antibodies were diluted 
in 1% BSA/PBS and incubated overnight at 4 °C. After washing with PBS, 
cells were stained with goat anti-mouse-FITC (Sigma) diluted 1:1000 and 
rabbit anti-goat-555 (Life technologies) diluted 1:2000 for Frizzled 1/2. 
All secondary antibodies were diluted in 1% BSA/PBS and incubated 
for 2 h at room temperature. Cells were washed with PBS X3 cells, then 
counterstained with DAPI (Sigma) for 15 min and stored in PBS.
MNP labeling of cells was determined using immunofluorescence to 
identify the dextran matrix of the MNP. After labeling with MNP, cells 
were fixed with 4% PFA in PBS (Fisher) for 10 min, permeabilized with 
0.1% Triton-X in PBS for 10 min, washed with PBS, then blocked with 
2% BSA/PBS for 2 h. Samples were then stained with an anti-dextran 
antibody (Stem Cell Technologies) diluted 1:1000 in 1% BSA in PBS 
overnight at 4 °C. Cells were then washed with PBS and stained with anti-
mouse-FITC secondary antibody (Sigma) diluted 1:1000 in 1% BSA in 
PBS for 1 h at room temperature. Cells were then washed with PBS and 
counterstained with DAPI to visualize cell nuclei and either Phalloidin–
Atto 565 (Sigma) to visualize F-actin or CM-Dil (Fisher) to visualize the 
cell membrane. For β-catenin staining, 24 h after treatment, cells were 
fixed with 90% methanol (Fisher) for 10 min. Cells were permeabilized 
with 0.1% Triton-X in PBS (Sigma) for 10 min and then then blocked 
in 2% BSA (Fisher) in PBS for 1 h at room temp. Cells were then 
incubated with anti-active β-catenin antibody (Millipore) diluted 1:1000 
in 1% BSA in PBS overnight at 4 °C. Afterward, cells were washed, then 
incubated with anti-Mouse-FITC secondary antibody (Sigma) in 0.1% 
BSA in PBS for 1 h at room temp. Cells were then washed with PBS 
and counterstained with DAPI (Sigma). Active β-catenin-positive cells 
were quantified by cell counting using ImageJ. A minimum of 100 cells 
were counted in each group. For dopaminergic marker studies, cells were 
PBS washed, then fixed with 4% PFA in PBS for 10 min. Cells were then 
permeabilized with 0.1% Triton-X100 (Sigma) in PBS for 10 min. Cells 
were washed with PBS, then blocked using 2% BSA (Fisher) in PBS for 
2 h. The blocking solution was aspirated, and cells were stained with 
primary antibodies as described below. Cells were stained with rabbit 
anti-tyrosine hydroxylase (TH) antibodies (Abcam) diluted 1:200 in 1% 
BSA/PBS and incubated overnight at 4 °C. Cells were washed with PBS 
X3 followed by incubation with Alexa Flour goat anti-rabbit IgG-594 
secondary antibodies (Life Technologies) diluted 1:500 in 1% BSA/PBS 
for 2 h at room temperature. Samples were then re-blocked with BSA as 
above, then stained with rat anti-dopamine transporter (DAT) antibodies 
diluted 1:500 in 1% BSA/PBS (Santa Cruz Biotech.) overnight at 4 °C. 
Cells were washed with PBS × 3 followed by incubation with Rabbit 
anti-Rat-488 secondary antibodies (Life Technologies) diluted 1:2000 in 
1% BSA/PBS for 2 h at room temperature. Cells were washed with PBS 
× 3; cells then counterstained with DAPI (Sigma) for 15 min and stored 
in PBS before imaging. TH and/or DAT-positive cells were quantified 
by cell counting using ImageJ. A minimum of 150 cells were counted 
in each group. Fluorescence microscopy was performed on an Eclipse 
Ti-S microscope (Nikon) or a Fluoview FV1200 laser scanning confocal 
microscope (Olympus) operating FV10-ASW (v4.2) imaging software.
Rat Brain Organotypic Slice Culture: Organotypic slice cultures were 
prepared from postnatal day 5–8 rat pups according to the interface 
method.[58] Pups were terminally anesthetized by intraperitoneal injection 
of pentobarbital in accordance with UK Animals (Scientific Procedures) 
Act 1986. Following decapitation, the brain was removed and placed 
in sterile ice-cold dissection medium composed of Gey’s balanced 
salt solution (GBSS, Sigma), 25 mm HEPES (Gibco), 2 mm GlutaMAX 
(Gibco), 36 mm d-glucose (Fisher), and antibiotic–antimycotic (Gibco, 
100 U mL−1 penicillin, 100 µg mL−1, 0.25 µg mL−1 amphotericin B). The 
hemispheres were bisected and 300 µm sagittal sections were cut at a 
10° angle using a vibratome (Leica). Following removal of the cortex and 
hippocampus, slices were placed in dissection medium for 1 h at 4 °C. 
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Three to four slices per hemisphere were transferred to 30 mm 0.4 µm 
pore membrane inserts (Millipore, PICM03050) in six-well plates and 
cultured for 7 days in slice culture medium composed of 50% Minimum 
Essential Medium (MEM, Gibco), 25% heat-inactivated horse serum 
(Gibco), 25% Hank’s Balanced Salt Solution (HBSS, Gibco), 25 mm 
HEPES, 2 mm GlutaMAX, 36 mm d-glucose, and antimitotic–antimycotic. 
The medium was changed every 2–3 days. After 7 days, the medium was 
changed to serum-free medium composed of Neurobasal A medium 
(Gibco), B27 (Gibco), 25 mm HEPES, 2 mm GlutaMAX, 36 mm d-glucose, 
and antimitotic-antimycotic.
Delivery of SH-SY5Y Cells into Slices: SH-SY5Y cells were first labeled 
with the membrane tracker Pkh26 (Sigma), and then tagged with MNPs 
as described above. Approximately, 4.105 cells were delivered into 
the striatum of triplicate slices by pipette with the aid of a dissection 
microscope. Serum-free medium was supplemented with 10 mm RA 
for 3 days followed by serum-free medium supplemented with 80 nm 
PMA for further 4 days. Magnetic stimulation was performed in 3 × 1-h 
sessions over 7 days; control slices were incubated under identical 
conditions but without loading. After 7 days, slices were washed with 
PBS and fixed with 4% PFA (Sigma) for 30 min . Slices were washed and 
stored in PBS prior to staining.
Organotypic Slice Immunohistochemistry: Slices were blocked in PBS 
containing 10% normal goat serum (Vector Labs), 1% triton X-100 
(Sigma) for 2 h at room temperature, followed by incubation with 
tyrosine hydroxylase antibody (1:1000, Millipore) in antibody solution 
(PBS containing 10% normal goat serum, 0.3% triton X-100) for 3 days 
at 4 °C. Slices were washed 3 times with PBS followed by incubation with 
Alexa Fluor goat anti-rabbit 488 antibody (1:500, Life Technologies) in 
antibody solution for 3 h at room temperature. Slices were washed three 
times with PBS, counterstained with DAPI for 15 min, mounted onto 
slides, and coverslipped.
Statistical Analysis: All data are presented as means +/− SEM or SD as 
stated. Statistical significance at 95% confidence level was determined 
using 1-way ANOVA with post hoc Tukey’s tests using Mini-tab (v16). 
Data were tested for normality and equal variance before analysis using 
Mini-tab.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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